NCT04116528View on ClinicalTrials.gov

Opiate Suicide Study in Patients With Major Depression

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

April 28, 2025

Study Completion Date

July 1, 2026

Conditions
Major Depressive Disorder
Interventions
DRUG

Ketamine

0.5mg/kg

DRUG

Buprenorphine

Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet

DRUG

Placebo oral tablet

Buprenorphine or Placebo orally dissolving tablet

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04116528 - Opiate Suicide Study in Patients With Major Depression | Biotech Hunter | Biotech Hunter